Initial Submission DARZALEX (Vetter)

Reg No. 1C 31/60 (NBC)

Variation submission

| Application number | Scope | Approval date | Product Information affected | Summary |
|--------------------|---------------------------------|---------------|------------------------------------|---------|
| 15178/61 (NB) | MiV-PA9 Change of the test | 10 Jan 2019 | | |
| | procedure of non-compendial | | | |
| | drug substance | | | |
| | MiV-N7 Withdrawal/deletion of | | | |
| | the alternative manufacturer(s) | | | |
| | (for drug substance and/or drug | | | |
| | product and/or packager) | | | |
| 15176/61 (NB) | MiV-PA2 Change of product | 8 Jan 2019 | Patient information leaflet | |
| | labeling (in accordance to | | Summary of Product Characteristics | |
| | country specific labeling | | | |
| | requirement) | | | |
| 15091/61 (NB) | MaV-2 Change of content of | 6 Oct 2018 | Patient information leaflet | |
| | product labeling | | | |
| 15020/61 (NB) | Non-AVG | 10 Sep 2018 | | |
| 15001/61 (NB) | MaV-1 Change and/or | 10 Sep 2018 | Patient information leaflet | |
| | additional indication/dosing | | Summary of Product Characteristics | |
| | regimen/patient | | | |

| Application number | Scope | Approval date | Product Information affected | Summary |
|--------------------|----------------------------------|---------------|------------------------------|---------|
| | population/inclusion of clinical | | | |
| | information extending the | | | |
| | usage of the product | | | |
| 15037/60 (NB) | MaV-15 Extension of shelf-life | 28 May 2018 | | |
| | of the drug product | | | |
| | MiV-PA10 Change of shelf-life | | | |
| | or retest period for drug | | | |
| | substance | | | |
| | Non-AVG | | | |